Loading…
AUROBEVERINE MR is a brand name for Mebeverine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the symptomatic relief of irritable bowel syndrome in adults.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults:
One capsule of 200 mg twice daily; one in the morning and one in the evening. There are no safety risks for continued use up to a period of 1 year. However, once the desired effect is achieved after several weeks, the dose can be gradually reduced.
If one or more doses are missed, the patient should continue with the next dose as prescribed; the missed dose(s) should not be taken in addition to the regular dose. Paediatric Population Aurobeverine MR is not recommended for use in children and adolescents below 18, due to insufficient data on safety and efficacy.
Duration of use is not limited. If one or more doses are missed, the patient should continue with the next dose as prescribed; the missed dose(s)should not be taken in addition to the regular dose. Special Population No posology studies in elderly, renal and/or hepatic impaired patients have been performed.
No specific risk for elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients. Method of administration Aurobeverine MR should be swallowed with a sufficient amount of water (at least 100 ml water).
2).
The following adverse reactions have been reported spontaneously during postmarketing use. A precise frequency cannot be estimated from available data. Allergic reactions mainly but not exclusively limited to the skin have been observed.
Immune system disorders:
Hypersensitivity (anaphylactic reactions).
Skin and subcutaneous tissue disorders:
Urticaria, angioedema, face oedema, exanthema. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple Store.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltese insufficiency should not take this medicine.
1
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Mebeverine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.